Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in China (V260-077)

First published 03/09/2020

Last updated 21/05/2025

EU PAS number:

EUPAS36666

Study

Ongoing

Documents

Study protocol

Initial protocol

V260-077-00-v2-China PMC-Prot_Final Redaction Part 1 Pages 1-28

English (631.4 KB - PDF)View document

Updated protocol

V260-077-V6.0-final-redaction.pdf

First published: 13/12/2024

English (700.3 KB - PDF)View document

Study results

Study report

Other information

Study, other information

V260-077-00-v2-China PMC-Prot_Final Redaction Part 2 Pages 29-51_1

English (349.89 KB - PDF)View document

V260-077-00-v4_protocol_final-redaction

English (1.56 MB - PDF)View document

V260-077-00-v5-Protocol_final-redaction.pdf

English (395.08 KB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs